Clinical trials: Helicobacter Pylori Resistance
Helicobacter Pylori Infection
New Strategy for the Detection and Treatment of Helicobacter Pylori Infections in Primary Care Guided by a Non-invasive PCR in Stool
In France, every year 1 million people are explored for Helicobacter pylori infection and 200,000 receive eradication treatment.
- Trial name
- HEPYPRIM (NCT05495854)
- Testing
- PCR test in the stool, Hp serology and gastroscopy
- Where
- 13 sites in France
- Volunteers
- 245 people
- Sponsor
- Poitiers University Hospital
Gastritis
A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Using Clarithromycin
As the resistant rate of the Helicobacter pylori to some common antibiotics was rising，the eradication rate of the Helicobacter pylori with the standard triple therapy failed to exceed 70% in China，and had to drop out of the…
- Trial name
- NCT02923856
- Testing
- The results of clarithromycin susceptibility test of H. pylori isolates, Computer generated random number, randomly assigned into groups, The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups
- Where
- China
- Volunteers
- 672 people
- Sponsor
- Sanmen People's Hospital
Helicobacter Pylori Treatment Failure
High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection
No trial has examined the the efficacy of high dose amoxicillin based quadruple therapy as second-line treatment for Helicobacter pylori infection.
- Trial name
- NCT02175927
- Testing
- Lansoprazole, Bismuth Potassium Citrate, Metronidazole
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection
The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection.
Clarithromycin (CLA)、amoxicillin (AMO)、metronidazole (MET)、levofloxacin (LEV) and tetracycline (TET) are commonly used antibiotics for Helicobacter pylori (Hp) therapy.
- Trial name
- NCT03583476
- Testing
- Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole
- Where
- Taiwan
- Volunteers
- 1,821 people
- Sponsor
- National Taiwan University Hospital
Dyspepsia
Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
Peptic ulcer disease is the most common gastrointestinal disease. Antibiotic resistant Helicobacter pylori is a major problem worldwide.
- Trial name
- NCT00285688
- Testing
- gastroscopic examination
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Helicobacter Pylori Gastritis
Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.
The goal of this trial is to compare the non-inferiority efficacy and safety of two different treatment schemes: pantoprazole 80 mg + levofloxacin 500 mg + azithromycin 500 mg once daily (PLA, test) vs.
- Trial name
- NCT02726269
- Testing
- CLA (Clarithro+Lanso+Amoxi), PLA (Panto+Levoflox+Azithro)
- Volunteers
- 230 people
- Sponsor
- Asofarma de México S.A de C.V.
Helicobacter Pylori Infection, Antibiotic Resistant Infection
Optimal Tailored Treatment for H. Pylori Infection
The efficacy of the current standard triple therapy is at an unacceptably low level. Resistance to antibiotics is suspected to be the major cause of the low efficacy of standard triple therapy.
- Trial name
- NCT04462133
- Testing
- Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)
- Where
- South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Incheon St.Mary's Hospital
Helicobacter Pylori Infection, Chronic Gastritis
Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection
Successful H. pylori eradication therapy remains a challenge in medical practice. Despite promising data for first-line, second-line and rescue treatment options based on clinical trials as well as guidelines and expert…
- Trial name
- ESAMOX (NCT00455806)
- Testing
- esomeprazole, moxifloxacin, amoxicillin
- Where
- 9 sites in Germany
- Volunteers
- 132 people
- Sponsor
- Technische Universität Dresden
Helicobacter Pylori Gastritis, Helicobacter Eradication
Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia
The goal of this clinical trial is to learn if a modified bismuth-containing therapy for the treatment of helicobacter pylori infection works to treat chronic helicobacter pylori related gastritis in adults treated either for…
- Trial name
- MBISQ4HP (NCT07146594)
- Testing
- Modified bismuth-containing eradication treatment
- Volunteers
- 150 people
- Sponsor
- Athens Medical Center
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass…
- Trial name
- NCT01654549
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
Helicobacter Pylori Infection
Tailored Therapy for Clarithromycin-Resistant H. Pylori
Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been…
- Trial name
- NCT03431688
- Testing
- PAM, PBMT
- Where
- South Korea
- Volunteers
- 782 people
- Sponsor
- Kangdong Sacred Heart Hospital
H. Pylori Infection
H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy
The rate of H. pylori resistance to antimicrobial agents including clarithromycin (CAM) has increased worldwide. Eradication failure using triple therapy is strongly associated with CAM-resistant H. pylori.
- Trial name
- NCT05002595
- Testing
- H. pylori eradication
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Soonchunhyang University Hospital
Cure Rate of Helicobacter Pylori Infection
Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection
To test the efficacy of 14 day levofloxacin and bismuth-containing second-line therapy for resistant Helicobacter pylori infection, to compare with the classical quadruple therapy.
- Trial name
- NCT01742429
- Testing
- Proton pump inhibitor, Bismuth subsalicylate, Metronidazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
Compare efficacy and safety of 10-day triple therapy (rabeprazole, clarithromycin and amoxicillin) plus N-acetylcystein versus 10-day concomitant therapy (rabeprazole, clarithromycin, amoxicillin and metronidazole) for…
- Trial name
- NCT01572597
- Testing
- 10RAC+acetylcystein, 10RAC+metronidazole
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Helicobacter Pylori Infection
Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection
Up to now, there is few randomized, large scale study prospectively and simultaneously comparing the efficacy, adverse effects and patient adherence of high-dose dual therapy (HDDT) and bismuth-containing quadruple therapy (BQT)…
- Trial name
- NCT02490839
- Testing
- High-dose dual therapy (rabeprazole, amoxicillin), Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
- Where
- Taiwan
- Volunteers
- 450 people
- Sponsor
- National Taiwan University Hospital
Gastritis
A Relevance Study Between the Result of Clinical Drug Intervention and Next-generation Sequencing Technology Focused on Refractory Helicobacter Pylori Infection
Approximately 50% of people in the world are infected with H. pylori, and its eradication rate fail to exceed 80% and even fails into an unacceptable range.Various risk factors for infection include lower socioeconomic status…
- Trial name
- NCT02806674
- Testing
- The eradication times of the patients, The result of 13C-urea breath test after treatment
- Where
- 4 sites in China
- Volunteers
- 1,845 people
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
Helicobacter Pylori Infection
Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea
South Korea has the highest incidence of gastric cancer worldwide and Helicobacter pylori infection is still prevalent. Clarithromycin-containing triple therapy is still the primary therapy approved by the Korean government.
- Trial name
- NCT03665428
- Testing
- PAMB treatment (modified quadruple therapy), PBMT treatment (bismuth-containing quadruple therapy)
- Where
- South Korea
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Helicobacter Pylori Infection
Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori
The purpose of this study is to compare the eradication efficacy of 10-day triple therapy with 10-day sequential therapy with tetracycline or metronidazole.
- Trial name
- NCT01573975
- Testing
- 5RA-5RCM, 5RA-5RCT, 10RCA
- Where
- Taiwan
- Volunteers
- 345 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Helicobacter Pylori
Performances of a H. Pylori Stool PCR Test
Performance of a non-invasive test for the detection of Helicobacter pylori and its resistance to clarithromycin in stool by Real-Time PCR Amplidiag H. pylori + ClariR (Mobidiag).
- Trial name
- HEPYSTOOL (NCT03566004)
- Testing
- Stool specimen collection
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Poitiers University Hospital
Helicobacter Pylori Infection, Helicobacter Pylori Gastritis
Helicobacter Pylori Local Prevalence and Antibiotic Resistance
The clinical management of H. pylori infection depends essentially on two factors, prevalence and local resistance. In Germany, only limited data from rather small cohorts currently exist regarding both factors.
- Conditions
- Helicobacter Pylori Infection, Helicobacter Pylori Gastritis, Drug Resistant Bacterial Infection, Antibiotic Resistant Infection
- Trial name
- HelicoPTER (NCT05561504)
- Where
- Germany
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich